Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. 1988

S A Rosenberg, and B S Packard, and P M Aebersold, and D Solomon, and S L Topalian, and S T Toy, and P Simon, and M T Lotze, and J C Yang, and C A Seipp
Surgery Branch, National Cancer Institute, Bethesda, MD 20892.

Lymphocytes extracted from freshly resected melanomas can be expanded in vitro and can often mediate specific lysis of autologous tumor cells but not allogeneic tumor or autologous normal cells. We treated 20 patients with metastatic melanoma by means of adoptive transfer of these tumor-infiltrating lymphocytes and interleukin-2, after the patients had received a single intravenous dose of cyclophosphamide. Objective regression of the cancer was observed in 9 of 15 patients (60 percent) who had not previously been treated with interleukin-2 and in 2 of 5 patients (40 percent) in whom previous therapy with interleukin-2 had failed. Regression of cancer occurred in the lungs, liver, bone, skin, and subcutaneous sites and lasted from 2 to more than 13 months. Toxic effects of interleukin-2 occurred, although the treatment course was short (five days); these side effects were reversible. It appears that in patients with metastatic melanoma, this experimental treatment regimen can produce higher response rates than those achieved with interleukin-2 administered alone or with lymphokine-activated killer cells. It is too early to determine whether this new form of immunotherapy can improve survival, but further trials seem warranted.

UI MeSH Term Description Entries
D007167 Immunotherapy Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection. Immunotherapies
D007376 Interleukin-2 A soluble substance elaborated by antigen- or mitogen-stimulated T-LYMPHOCYTES which induces DNA synthesis in naive lymphocytes. IL-2,Lymphocyte Mitogenic Factor,T-Cell Growth Factor,TCGF,IL2,Interleukin II,Interleukine 2,RU 49637,RU-49637,Ro-23-6019,Ro-236019,T-Cell Stimulating Factor,Thymocyte Stimulating Factor,Interleukin 2,Mitogenic Factor, Lymphocyte,RU49637,Ro 23 6019,Ro 236019,Ro236019,T Cell Growth Factor,T Cell Stimulating Factor
D008214 Lymphocytes White blood cells formed in the body's lymphoid tissue. The nucleus is round or ovoid with coarse, irregularly clumped chromatin while the cytoplasm is typically pale blue with azurophilic (if any) granules. Most lymphocytes can be classified as either T or B (with subpopulations of each), or NATURAL KILLER CELLS. Lymphoid Cells,Cell, Lymphoid,Cells, Lymphoid,Lymphocyte,Lymphoid Cell
D008297 Male Males
D008545 Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445) Malignant Melanoma,Malignant Melanomas,Melanoma, Malignant,Melanomas,Melanomas, Malignant
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009362 Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site. Metastase,Metastasis,Metastases, Neoplasm,Metastasis, Neoplasm,Neoplasm Metastases,Metastases
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271

Related Publications

S A Rosenberg, and B S Packard, and P M Aebersold, and D Solomon, and S L Topalian, and S T Toy, and P Simon, and M T Lotze, and J C Yang, and C A Seipp
August 1994, Journal of the National Cancer Institute,
S A Rosenberg, and B S Packard, and P M Aebersold, and D Solomon, and S L Topalian, and S T Toy, and P Simon, and M T Lotze, and J C Yang, and C A Seipp
February 1995, Journal of the National Cancer Institute,
S A Rosenberg, and B S Packard, and P M Aebersold, and D Solomon, and S L Topalian, and S T Toy, and P Simon, and M T Lotze, and J C Yang, and C A Seipp
August 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
S A Rosenberg, and B S Packard, and P M Aebersold, and D Solomon, and S L Topalian, and S T Toy, and P Simon, and M T Lotze, and J C Yang, and C A Seipp
January 2003, Journal of immunotherapy (Hagerstown, Md. : 1997),
S A Rosenberg, and B S Packard, and P M Aebersold, and D Solomon, and S L Topalian, and S T Toy, and P Simon, and M T Lotze, and J C Yang, and C A Seipp
August 2012, Journal of translational medicine,
S A Rosenberg, and B S Packard, and P M Aebersold, and D Solomon, and S L Topalian, and S T Toy, and P Simon, and M T Lotze, and J C Yang, and C A Seipp
April 1992, Human gene therapy,
S A Rosenberg, and B S Packard, and P M Aebersold, and D Solomon, and S L Topalian, and S T Toy, and P Simon, and M T Lotze, and J C Yang, and C A Seipp
January 1992, Biotherapy (Dordrecht, Netherlands),
S A Rosenberg, and B S Packard, and P M Aebersold, and D Solomon, and S L Topalian, and S T Toy, and P Simon, and M T Lotze, and J C Yang, and C A Seipp
May 1994, Cancer immunology, immunotherapy : CII,
S A Rosenberg, and B S Packard, and P M Aebersold, and D Solomon, and S L Topalian, and S T Toy, and P Simon, and M T Lotze, and J C Yang, and C A Seipp
January 2023, Oncoimmunology,
S A Rosenberg, and B S Packard, and P M Aebersold, and D Solomon, and S L Topalian, and S T Toy, and P Simon, and M T Lotze, and J C Yang, and C A Seipp
May 2015, Clinical cancer research : an official journal of the American Association for Cancer Research,
Copied contents to your clipboard!